



December 28, 2012

Food and Drug Administration
Division of Dockets Management (HFA-305)
Department of Health and Human Services
5630 Fishers Lane,
Room 1061
Rockville, MD 20852

CITIZEN PETITION

Dear Sir or Madam,

The undersigned submits this Citizen Petition pursuant to the Federal Food, Drug and Cosmetic Act ("FD&C Act") and the Food and Drug Administration's ("FDA's") regulations at 21 CFR §§ 10.20, 10.30, and 314.93 to request that FDA amend the Approved Drug Products with Therapeutic Equivalence Evaluations (referred to as the "FDA's Orange Book") to designate Impax Pharmaceutical's Midodrine Hydrochloride Tablets, ANDA 076449, as the reference listed drug ("RLD"). Prior to its discontinuation, Proamatine was designated as the RLD for Midodrine Hydrochloride Tablets; 5 mg as NDA 19815 held by Shire LLC. However as noted in the attached Orange Book Reference as Attachment A, Proamatine has been discontinued

A. Action Requested

The undersigned requests that the Commissioner of Food and Drugs designate Impax Pharmaceutical's Midodrine Hydrochloride Tablets, ANDA 076449, as the RLD for the purposes of submitting an ANDA for a generic version of Midodrine Hydrochloride Tablets

B. State of Grounds

Proamatine 5 mg was assigned as the RLD and has since been discontinued. There is a sound basis for designating a new RLD. The orange book currently lists five approved suppliers of Midodrine Hydrochloride Tablets as documented in Attachment B. However, only Sandoz's and Impax's products are currently available in the US. Of the two available suppliers, Impax was the first approved ANDA and therefore we request it be listed as the RLD.

FDA-2013-P-0027

2013-~~7~~ CP

0756 12 DEC 31 AM 12:01



Without such a designation, the product will be shielded from generic competition. Therefore, the Petitioner is hereby requesting that the Impax product be designated as the RLD to permit the filing of ANDAs for Midodrine Hydrochloride Tablets.

C. Environmental Impact

The Petitioner claims a categorical exclusion from the requirement of an environmental assessment or environmental impact statement pursuant to 21 CFR § 25.31.

D. Economic Impact

Pursuant to 21 CFR § 10.30(b), the Petitioner will, upon request by the Commissioner, submit economic impact information.

E. Certification

The undersigned certifies that to the best of its knowledge, this petition includes all information on which the Petition relies, and that it includes representative data and information known to the Petitioner, that are unfavorable to the Petition.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Frederik Defesche', written over a series of horizontal lines.

Frederik Defesche
President
Tel: (760) 683-0901
Fax: (760) 301-0048
E-mail: fdefesche@custopharm.com

Attachments

U.S. Food & Drug Administration

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations[FDA Home](#)³**Active Ingredient Search Results from "OB_Rx" table for query on "Clotrimazole."**

Appl No	TE Code ⁴	RLD ⁵	Active Ingredient	Dosage Form; Route	Strength	Proprietary Name	Applicant
A076002 AB		No	BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE	CREAM; TOPICAL	EQ 0.05% BASE;1%	CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE	ACTAVIS MID ATLANTIC
A075502 AB		No	BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE	CREAM; TOPICAL	EQ 0.05% BASE;1%	CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE	FOUGERA PHARMS
N018827 AB		Yes	BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE	CREAM; TOPICAL	EQ 0.05% BASE;1%	LOTRISONE	MERCK SHARP DOHME
A075673 AB		No	BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE	CREAM; TOPICAL	EQ 0.05% BASE;1%	CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE	TARO
A076516 AB		No	BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE	LOTION; TOPICAL	EQ 0.05% BASE;1%	CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE	FOUGERA PHARMS
N020010 AB		Yes	BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE	LOTION; TOPICAL	EQ 0.05% BASE;1%	LOTRISONE	SCHERING CORP
A076493 AB		No	BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE	LOTION; TOPICAL	EQ 0.05% BASE;1%	CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE	TARO
A078338 AB		No	CLOTRIMAZOLE	CREAM; TOPICAL	1%	CLOTRIMAZOLE	FOUGERA PHARMS
A090219 AB		No	CLOTRIMAZOLE	CREAM; TOPICAL	1%	CLOTRIMAZOLE	GLENMARK PHARMS
A072640 AB		Yes	CLOTRIMAZOLE	CREAM; TOPICAL	1%	CLOTRIMAZOLE	TARO
N018181 AT		Yes	CLOTRIMAZOLE	SOLUTION; TOPICAL	1%	MYCELEX	BAYER HLTHCARE
A074580 AT		No	CLOTRIMAZOLE	SOLUTION; TOPICAL	1%	CLOTRIMAZOLE	TARO
A073306 AT		No	CLOTRIMAZOLE	SOLUTION; TOPICAL	1%	CLOTRIMAZOLE	TEVA
N018713 AB		Yes	CLOTRIMAZOLE	TROCHE/LOZENGE; 10MG ORAL		MYCELEX	BAYER HLTHCARE
A076763 AB		No	CLOTRIMAZOLE	TROCHE/LOZENGE; 10MG ORAL		CLOTRIMAZOLE	PADDOCK LLC
A076387 AB		No	CLOTRIMAZOLE	TROCHE/LOZENGE; 10MG ORAL		CLOTRIMAZOLE	ROXANE

ATTACHMENT A

Return to Electronic Orange Book Home Page ⁶

FDA/Center for Drug Evaluation and Research

Office of Generic Drugs

Division of Labeling and Program Support

Update Frequency:

Orange Book Data - **Monthly**

Generic Drug Product Information & Patent Information - **Daily**

Orange Book Data Updated Through November, 2012

Patent and Generic Drug Product Data Last Updated: December 27, 2012

Links on this page:

1. <http://www.addthis.com/bookmark.php?u508=true&v=152&username=fdomain>
2. <http://www.addthis.com/bookmark.php>
3. <http://www.fda.gov/default.htm>
4. [http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ucm079068.htm#Therapeutic
Equivalence-Related Terms](http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ucm079068.htm#TherapeuticEquivalence-RelatedTerms)
5. [http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ucm079068.htm#Reference
Listed Drug](http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ucm079068.htm#ReferenceListedDrug)
6. [../default.cfm](#)

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.

- Accessibility
- Contact FDA
- Careers
- FDA Basics
- FOIA
- No Fear Act
- Site Map
- Transparency
- Website Policies

U.S. Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
Ph. 1-888-INFO-FDA (1-888-463-6332)
Email FDA

- [fda.gov](#)

-



- For Government
- For Press

- Advisory Committees
- Science & Research
- Regulatory Information
- Safety
- Emergency Preparedness
- International Programs
- News & Events
- Training and Continuing Education
- Inspections/Compliance
- State & Local Officials
- Consumers
- Industry
- Health Professionals



U.S. Department of Health & Human Services

Links on this page:

1. <http://www.addthis.com/bookmark.php?u508=true&v=152&username=fdomain>
2. <http://www.addthis.com/bookmark.php>
3. <http://www.fda.gov/default.htm>
4. [http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ucm079068.htm#Therapeutic
Equivalence-Related Terms](http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ucm079068.htm#TherapeuticEquivalence-RelatedTerms)
5. [http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ucm079068.htm#Reference
Listed Drug](http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ucm079068.htm#ReferenceListedDrug)
6. [../default.cfm](#)

U.S. Food & Drug Administration

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

[FDA Home](#)² [Drug Databases](#)⁴ [Orange Book](#)⁵

Search results from the "OB_Rx" table for query on "018713."

Active Ingredient:	CLOTRIMAZOLE
Dosage Form;Route:	TROCHE/LOZENGE; ORAL
Proprietary Name:	MYCELEX
Applicant:	BAYER HLTHCARE
Strength:	10MG
Application Number:	N018713
Product Number:	001
Approval Date:	Jun 17, 1983
Reference Listed Drug	Yes
RX/OTC/DISCN:	RX
TE Code:	AB
Patent and Exclusivity Info for this product:	View

[Return to Electronic Orange Book Home Page](#)⁶

FDA/Center for Drug Evaluation and Research

Office of Generic Drugs

Division of Labeling and Program Support

Update Frequency:

Orange Book Data - **Monthly**

Generic Drug Product Information & Patent Information - **Daily**

Orange Book Data Updated Through November, 2012

Patent and Generic Drug Product Data Last Updated: December 27, 2012

Links on this page:

1. <http://www.addthis.com/bookmark.php?u508=true&v=152&username=fdomain>
2. <http://www.addthis.com/bookmark.php>
3. <http://www.fda.gov/default.htm>
4. <http://www.fda.gov/Drugs/InformationOnDrugs/default.htm>
5. [../default.cfm](#)
6. [../default.cfm](#)

Note: If you need help accessing information in different file formats, see [Instructions for Downloading Viewers and Players](#).

- [Accessibility](#)
- [Contact FDA](#)
- [Careers](#)
- [FDA Basics](#)
- [FOIA](#)

- Site Map
- Transparency
- Website Policies

U.S. Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
Ph. 1-888-INFO-FDA (1-888-463-6332)
Email FDA

- [USA.gov](#)

-

- [FDA.gov](#)

- [FDA.gov](#)

- [FDA.gov](#)

- [FDA.gov](#)

- [FDA.gov](#)

- For Government
- For Press
- Combination Products
- Advisory Committees
- Science & Research
- Regulatory Information
- Safety
- Emergency Preparedness
- International Programs
- News & Events
- Training and Continuing Education
- Inspections/Compliance
- State & Local Officials
- Consumers
- Industry
- Health Professionals



U.S. Department of Health & Human Services

Links on this page:

1. <http://www.addthis.com/bookmark.php?u508=true&v=152&username=fdamain>
2. <http://www.addthis.com/bookmark.php>
3. <http://www.fda.gov/default.htm>
4. <http://www.fda.gov/Drugs/InformationOnDrugs/default.htm>
5. [../default.cfm](#)
6. [../default.cfm](#)

U.S. Food & Drug Administration

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

1

[FDA Home](#)² [Drug Databases](#)⁴ [Orange Book](#)⁵

Search results from the "OB_Rx" table for query on "076387."

Active Ingredient:	CLOTRIMAZOLE
Dosage Form;Route:	TROCHE/LOZENGE; ORAL
Proprietary Name:	CLOTRIMAZOLE
Applicant:	ROXANE
Strength:	10MG
Application Number:	A076387
Product Number:	001
Approval Date:	Jul 29, 2004
Reference Listed Drug	No
RX/OTC/DISCN:	RX
TE Code:	AB
Patent and Exclusivity Info for this product:	View

[Return to Electronic Orange Book Home Page](#)⁶

FDA/Center for Drug Evaluation and Research

Office of Generic Drugs

Division of Labeling and Program Support

Update Frequency:

Orange Book Data - **Monthly**

Generic Drug Product Information & Patent Information - **Daily**

Orange Book Data Updated Through November, 2012

Patent and Generic Drug Product Data Last Updated: December 27, 2012

Links on this page:

1. <http://www.addthis.com/bookmark.php?u508=true&v=152&username=fdamain>
2. <http://www.addthis.com/bookmark.php>
3. <http://www.fda.gov/default.htm>
4. <http://www.fda.gov/Drugs/InformationOnDrugs/default.htm>
5. [../default.cfm](#)
6. [../default.cfm](#)

Note: If you need help accessing information in different file formats, see [Instructions for Downloading Viewers and Players](#).

- [Accessibility](#)
- [Contact FDA](#)
- [Careers](#)
- [FDA Basics](#)
- [FOIA](#)

- Site Map
- Transparency
- Website Policies

U.S. Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
Ph. 1-888-INFO-FDA (1-888-463-6332)
Email FDA

• [USA.gov](#)

•

• [FDA](#)

• [FDA](#)

• [FDA](#)

• [FDA](#)

• [FDA](#)

- For Government
- For Press
- Combination Products
- Advisory Committees
- Science & Research
- Regulatory Information
- Safety
- Emergency Preparedness
- International Programs
- News & Events
- Training and Continuing Education
- Inspections/Compliance
- State & Local Officials
- Consumers
- Industry
- Health Professionals



U.S. Department of Health & Human Services

Links on this page:

1. <http://www.addthis.com/bookmark.php?u508=true&v=152&username=fdomain>
2. <http://www.addthis.com/bookmark.php>
3. <http://www.fda.gov/default.htm>
4. <http://www.fda.gov/Drugs/InformationOnDrugs/default.htm>
5. [../default.cfm](#)
6. [../default.cfm](#)

U.S. Food & Drug Administration

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

[FDA Home](#)² [Drug Databases](#)⁴ [Orange Book](#)⁵

Search results from the "OB_Rx" table for query on "076763."

Active Ingredient:	CLOTTRIMAZOLE
Dosage Form;Route:	TROCHE/LOZENGE; ORAL
Proprietary Name:	CLOTTRIMAZOLE
Applicant:	PADDOCK LLC
Strength:	10MG
Application Number:	A076763
Product Number:	001
Approval Date:	Oct 28, 2005
Reference Listed Drug	No
RX/OTC/DISCN:	RX
TE Code:	AB
Patent and Exclusivity Info for this product:	View

[Return to Electronic Orange Book Home Page](#)⁶

FDA/Center for Drug Evaluation and Research

Office of Generic Drugs

Division of Labeling and Program Support

Update Frequency:

Orange Book Data - **Monthly**

Generic Drug Product Information & Patent Information - **Daily**

Orange Book Data Updated Through November, 2012

Patent and Generic Drug Product Data Last Updated: December 27, 2012

Links on this page:

1. <http://www.addthis.com/bookmark.php?u508=true&v=152&username=fdomain>
2. <http://www.addthis.com/bookmark.php>
3. <http://www.fda.gov/default.htm>
4. <http://www.fda.gov/Drugs/InformationOnDrugs/default.htm>
5. [../default.cfm](#)
6. [../default.cfm](#)

Note: If you need help accessing information in different file formats, see [Instructions for Downloading Viewers and Players](#).

- [Accessibility](#)
- [Contact FDA](#)
- [Careers](#)
- [FDA Basics](#)
- [FOIA](#)

- Site Map
- Transparency
- Website Policies

U.S. Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
Ph. 1-888-INFO-FDA (1-888-463-6332)
Email FDA

- FDA.gov

-

- 

- 

- 

- 

- 

- For Government
- For Press
- Combination Products
- Advisory Committees
- Science & Research
- Regulatory Information
- Safety
- Emergency Preparedness
- International Programs
- News & Events
- Training and Continuing Education
- Inspections/Compliance
- State & Local Officials
- Consumers
- Industry
- Health Professionals



U.S. Department of Health & Human Services

Links on this page:

1. <http://www.addthis.com/bookmark.php?u508=true&v=152&username=fdamain>
2. <http://www.addthis.com/bookmark.php>
3. <http://www.fda.gov/default.htm>
4. <http://www.fda.gov/Drugs/InformationOnDrugs/default.htm>
5. <http://www.fda.gov/default.cfm>
6. <http://www.fda.gov/default.cfm>

UPS Internet Shipping: View/Print Label

1. **Ensure there are no other shipping or tracking labels attached to your package.** Select the Print button on the print dialog box that appears. Note: If your browser does not support this function select Print from the File menu to print the label.
2. **Fold the printed sheet containing the label at the line so that the entire shipping label is visible.** Place the label on a single side of the package and cover it completely with clear plastic shipping tape. Do not cover any seams or closures on the package with the label. Place the label in a UPS Shipping Pouch. If you do not have a pouch, affix the folded label using clear plastic shipping tape over the entire label.

3. GETTING YOUR SHIPMENT TO UPS

UPS locations include the UPS Store®, UPS drop boxes, UPS customer centers, authorized retail outlets and UPS drivers.





Find your closest UPS location at: www.ups.com/dropoff

Take your package to any location of The UPS Store®, UPS Drop Box, UPS Customer Center, UPS Alliances (Office Depot® or Staples®) or Authorized Shipping Outlet near you. Items sent via UPS Return Services(SM) (including via Ground) are also accepted at Drop Boxes. To find the location nearest you, please visit the 'Find Locations' Quick link at ups.com.

Customers with a Daily Pickup

Your driver will pickup your shipment(s) as usual.

FOLD HERE

<p>FRED DEFESCHE 7604817811 CUSTOPHARM, INC. 2325 CAMINO VIDA ROBLE CARLSBAD CA 92009</p> <p>SHIP TO: DIV. OF DOCKET'S MANAGEMENT HFA-305 FOOD AND DRUG ADMINISTRATION ROOM 1061 5630 FISHERS LANE ROCKVILLE MD 20857-0001</p>	<p>2 LBS PAK 1 OF 1</p> <p>MD 207 9-83</p>  	<p>UPS NEXT DAY AIR</p> <p>1</p> <p>TRACKING #: 1Z 72A 98R 01 9346 7512</p>		<p>BILLING: P/P</p>  <p>UPS 14.5.29 WNTNVS0 33.0A 10/2012</p>
--	--	---	--	---